GlaxoSmithKline plc (GSK) Receives Buy Rating from HSBC Holdings PLC
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reiterated by analysts at HSBC Holdings PLC in a report released on Wednesday. They currently have a GBX 1,925 ($25.32) price target on the stock. HSBC Holdings PLC’s price objective would indicate a potential upside of 47.45% from the company’s previous close.
Several other analysts also recently commented on the stock. Societe Generale reaffirmed a “sell” rating on shares of GlaxoSmithKline plc in a research report on Thursday, November 9th. Berenberg Bank reduced their price objective on shares of GlaxoSmithKline plc from GBX 1,835 ($24.14) to GBX 1,760 ($23.15) and set a “buy” rating for the company in a research report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($19.07) price objective on shares of GlaxoSmithKline plc and gave the stock a “sell” rating in a research report on Monday, November 6th. Deutsche Bank AG set a GBX 1,610 ($21.18) price objective on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research report on Friday, October 27th. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a GBX 1,450 ($19.07) price objective on shares of GlaxoSmithKline plc in a research report on Friday, October 27th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company’s stock. GlaxoSmithKline plc currently has an average rating of “Hold” and a consensus price target of GBX 1,586.67 ($20.87).
Shares of GlaxoSmithKline plc (LON:GSK) traded up GBX 3 ($0.04) during mid-day trading on Wednesday, hitting GBX 1,305.50 ($17.17). 7,313,436 shares of the stock traded hands, compared to its average volume of 10,320,000. GlaxoSmithKline plc has a one year low of GBX 1,294 ($17.02) and a one year high of GBX 1,724.50 ($22.68).
ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Receives Buy Rating from HSBC Holdings PLC” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/23/glaxosmithkline-plc-gsk-receives-buy-rating-from-hsbc-holdings-plc.html.
In related news, insider Simon Dingemans acquired 1,076 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were acquired at an average cost of GBX 1,527 ($20.08) per share, for a total transaction of £16,430.52 ($21,610.57). Also, insider Urs Rohner acquired 473 shares of the company’s stock in a transaction on Wednesday, October 25th. The shares were bought at an average price of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). Over the last quarter, insiders purchased 1,576 shares of company stock worth $2,400,376.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.